Swift Christopher 4
4 · HARTFORD INSURANCE GROUP, INC. · Filed Feb 6, 2026
Research Summary
AI-generated summary of this filing
Hartford (HIG) CEO Christopher Swift Exercises Options, Sells 100,970 Shares
What Happened
- Christopher Swift, Chairman & CEO of Hartford Insurance Group (HIG), exercised 100,970 stock options on Feb 4, 2026 (exercise price $48.89) and immediately sold the 100,970 shares in open-market transactions the same day. The exercise cost was $4,936,423; the two sales generated aggregate proceeds of $14,214,272. This was a sale (routine liquidity) rather than a new purchase.
Key Details
- Transaction date: 2026-02-04 (Form 4 filed 2026-02-06; appears timely).
- Option exercise: 100,970 shares acquired at $48.89 each; total cost $4,936,423. (M = option exercise)
- Sales: 19,778 shares sold at a weighted avg $141.19 (range $141.00–$141.47) for $2,792,482; 81,192 shares sold at a weighted avg $140.68 (range $140.00–$140.99) for $11,421,790. Total sale proceeds ≈ $14,214,272.
- Net proceeds before taxes/fees ≈ $9,277,849 (sale proceeds minus exercise cost).
- Shares owned after transaction: not specified in the provided excerpt.
- Notable footnotes: sales were effected under a Rule 10b5‑1 trading plan adopted Nov 3, 2025. The exercised options were granted in 2017 and are scheduled to expire Feb 28, 2027. A separate Form line shows the derivative instrument was canceled on exercise (zero-dollar disposition), which is standard when options are converted to shares.
Context
- Because the options were exercised and the resulting shares were sold the same day under a pre-established 10b5‑1 plan, this is effectively a cashless exercise for liquidity purposes rather than a fresh buy signal. Such transactions are common for executives exercising long‑held grants; they are factual disclosures of conversion and sale, not an explicit statement of company outlook.
Insider Transaction Report
Form 4
Swift Christopher
DirectorChairman and CEO
Transactions
- Exercise/Conversion
Common Stock
2026-02-04$48.89/sh+100,970$4,936,423→ 295,786.948 total - Sale
Common Stock
[F1][F2]2026-02-04$141.19/sh−19,778$2,792,482→ 276,008.948 total - Sale
Common Stock
[F1][F3]2026-02-04$140.68/sh−81,192$11,421,790→ 194,816.948 total - Exercise/Conversion
Stock Option
[F4]2026-02-04−100,970→ 0 totalExercise: $48.89Exp: 2027-02-28→ Common Stock (100,970 underlying)
Holdings
- 40,003(indirect: By Spouse)
Common Stock
- 95,386(indirect: By Trust)
Common Stock
- 60,865(indirect: By Trust)
Common Stock
- 352,263
Stock Option
[F5]Exercise: $49.01Exp: 2029-02-26→ Common Stock (352,263 underlying) - 310,820
Stock Option
[F6]Exercise: $51.87Exp: 2031-02-23→ Common Stock (310,820 underlying) - 284,819
Stock Option
[F7]Exercise: $53.81Exp: 2028-02-27→ Common Stock (284,819 underlying) - 327,679
Stock Option
[F8]Exercise: $55.27Exp: 2030-02-25→ Common Stock (327,679 underlying) - 301,932
Stock Option
[F9]Exercise: $69.41Exp: 2032-02-23→ Common Stock (301,932 underlying) - 248,933
Stock Option
[F10]Exercise: $78.28Exp: 2033-02-28→ Common Stock (248,933 underlying) - 116,414
Stock Option
[F11]Exercise: $95.74Exp: 2034-02-27→ Common Stock (116,414 underlying) - 99,403
Stock Option
[F12]Exercise: $116.41Exp: 2035-02-25→ Common Stock (99,403 underlying)
Footnotes (12)
- [F1]The transaction reported on this Form 4 was effected pursuant to a trading plan previously adopted by Mr. Swift on November 3, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The exercised options were granted to Mr. Swift in 2017 and are scheduled to expire on February 28, 2027.
- [F10]One-third of the options became exercisable on February 28, 2024, an additional one-third of the options became exercisable on February 28, 2025 and the remaining one-third of the options will become exercisable on February 28, 2026, the third anniversary of the grant date.
- [F11]One-third of the options became exercisable on February 27, 2025, an additional one-third of the options will become exercisable on February 27, 2026 and the remaining one-third of the options will become exercisable on February 27, 2027, the third anniversary of the grant date.
- [F12]One-third of the options will become exercisable on February 25, 2026, an additional one-third of the options will become exercisable on February 25, 2027 and the remaining one-third of the options will become exercisable on February 25, 2028, the third anniversary of the grant date.
- [F2]Price reflected is the weighted average sale price for shares sold. The range of sales prices for the transactions reported was $141 - $141.47 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]Price reflected is the weighted average sale price for shares sold. The range of sales prices for the transactions reported was $140 - $140.99 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]The options became fully exercisable on February 28, 2020, the third anniversary of the grant date.
- [F5]The options became fully exercisable on February 26, 2022, the third anniversary of the grant date.
- [F6]The options became fully exercisable on February 23, 2024, the third anniversary of the grant date.
- [F7]The options became fully exercisable on February 27, 2021, the third anniversary of the grant date.
- [F8]The options became fully exercisable on February 25, 2023, the third anniversary of the grant date.
- [F9]The options became fully exercisable on February 23, 2025, the third anniversary of the grant date.
Signature
Anthony J. Salerno, Jr., Attorney-in-Fact|2026-02-06